EXAI
EXSCIENTIA PLC (EXAI)
$11.052.31%▲
Live
Performance
$10.3001
Day's Range
$11.23
$4.09
52-Week Range
$22.99
| Returns % | |
| 1 month return | 79.7% |
| 3 month return | 56.07% |
| 1 year return | 48.96% |
| 5 year return | 60.15% |
Highlights
| Market Capitalization | 1.1B |
| Book Value | $4.16 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -1.33 |
| Wall Street Target Price | 15.0 |
Company Financials
Peers
Analyst Recommendation
based on 10 analysts ratings
Buy
80%
Buy
20%
Hold
0%
Sell
Based on 10 Wall street analysts offering stock ratings for EXSCIENTIA PLC(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 35.75%Current
$11.05
Target
$15.0
Recommendation Trend
Based on 10 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 8 | 8 | 8 |
| Hold | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 1.0 |
| Enterprise Value | -50277077 |
| Enterprise Value/Revenue | 3.05 |
| Enterprise Value/Ebitda | 0.47 |
Technicals
| 50 Day MA | 5.71 |
| 200 Day MA | 8.84 |
Institutional Holdings
SB Global Advisers Ltd
4.62%
Baillie Gifford & Co Limited.
3.97%
Junked Platinum Investment Management Ltd
2.29%
LAURION CAPITAL MANAGEMENT LP
1.74%
Marshall Wace Asset Management Ltd
1.33%
Bill & Melinda Gates Foundation
1.29%
Company Information
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Exscientia's pipeline of internal and partnered programmes demonstrates its ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials. Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka.
| Organization | EXSCIENTIA PLC |
| Employees | 285 |
| CEO | Prof. Andrew L. Hopkins DPHIL, FRSE FRSC |
| Industry | Healthcare |
Discover more
Frequently Asked Questions
What is EXSCIENTIA PLC share price today?
Can Indians buy EXSCIENTIA PLC shares?
How can I buy EXSCIENTIA PLC shares from India?
Can Fractional shares of EXSCIENTIA PLC be purchased?
What are the documents required to start investing in EXSCIENTIA PLC stocks?
What are today’s High and Low prices of EXSCIENTIA PLC?
What are today’s traded volumes of EXSCIENTIA PLC?
What is today’s market capitalisation of EXSCIENTIA PLC?
What is the 52 Week High and Low Range of EXSCIENTIA PLC?
How much percentage EXSCIENTIA PLC is down from its 52 Week High?
How much percentage EXSCIENTIA PLC is up from its 52 Week low?
What are the historical returns of EXSCIENTIA PLC?
Who is the Chief Executive Officer (CEO) of EXSCIENTIA PLC?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*